CHRS
Coherus BioSciences Inc
1.20$
-7.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 1,837.1% | 1,137.0% | 251.5% | 708.0% | 133.8% | 10,316.9% | 207.9% | 4.8% | 7.9% | 17.6% | 33.2% | 61.8% | 44.0% | 42.1% | |
| -1,737.1% | -1,037.0% | -151.5% | -608.0% | -33.8% | -10,216.9% | -107.9% | 95.2% | 92.1% | 82.4% | 66.8% | 38.2% | 56.0% | 57.9% | |
| 1,837.1% | 1,137.0% | 251.5% | 709.2% | 133.8% | 10,436.3% | 7,084.8% | 26.5% | 30.0% | 111.2% | 94.5% | 42.5% | 35.0% | 248.9% | |
| 291.3% | 271.4% | 56.5% | 120.0% | 27.1% | 4,582.5% | 6,052.5% | 37.2% | 28.4% | 49.3% | 89.1% | 67.9% | 52.3% | 238.6% | |
| 2,128.3% | 1,408.4% | 307.9% | 829.2% | 161.0% | 15,018.8% | 13,137.3% | 64.9% | 59.2% | 163.2% | 188.5% | 117.2% | 97.8% | 483.7% | |
| -2,028.3% | -1,308.4% | -207.9% | -729.2% | -61.0% | -14,918.8% | -13,137.3% | 30.3% | 32.9% | -80.8% | -121.7% | -79.0% | -41.8% | -425.7% | |
| 79.7% | 192.4% | 12.5% | 0.1% | 4.2% | 613.9% | 622.4% | 4.9% | 4.4% | 7.0% | 15.4% | 15.8% | 10.2% | 21.3% | |
| -1,738.7% | -1,949.7% | -280.3% | -745.4% | -67.2% | -15,314.0% | -13,458.2% | 26.1% | 28.5% | -87.9% | -138.2% | -92.6% | 10.7% | -434.2% | |
| 449.1% | -256.5% | -49.5% | -24.5% | 0.3% | 606.7% | 301.5% | 0.8% | 0.7% | 5.9% | 16.5% | -0.1% | 10.7% | -789.2% | |
| -1,738.7% | -1,949.7% | -280.1% | -743.2% | -67.0% | -15,306.6% | -13,453.7% | 25.2% | 27.8% | -87.9% | -138.2% | -92.5% | 10.7% | -403.8% | |
| -1,647.3% | -1,742.6% | -265.9% | -739.1% | -61.4% | -14,481.7% | -13,137.3% | 31.2% | 34.0% | -79.8% | -121.1% | -75.4% | 22.8% | -403.6% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.